F&V Capital Management LLC reduced its stake in Medtronic plc. (NYSE:MDT) by 4.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 68,720 shares of the medical technology company’s stock after selling 2,880 shares during the period. Medtronic accounts for approximately 2.9% of F&V Capital Management LLC’s investment portfolio, making the stock its 14th biggest position. F&V Capital Management LLC’s holdings in Medtronic were worth $5,549,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Medtronic by 2.4% in the second quarter. Vanguard Group Inc. now owns 104,776,036 shares of the medical technology company’s stock valued at $9,298,872,000 after acquiring an additional 2,454,380 shares in the last quarter. BlackRock Inc. grew its stake in shares of Medtronic by 2.8% in the second quarter. BlackRock Inc. now owns 89,512,229 shares of the medical technology company’s stock valued at $7,944,210,000 after acquiring an additional 2,476,853 shares in the last quarter. Artisan Partners Limited Partnership grew its stake in shares of Medtronic by 1.1% in the third quarter. Artisan Partners Limited Partnership now owns 23,853,034 shares of the medical technology company’s stock valued at $1,855,050,000 after acquiring an additional 269,814 shares in the last quarter. Lazard Asset Management LLC grew its stake in shares of Medtronic by 43.8% in the second quarter. Lazard Asset Management LLC now owns 19,669,866 shares of the medical technology company’s stock valued at $1,745,699,000 after acquiring an additional 5,991,094 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Medtronic by 1.4% in the third quarter. Wells Fargo & Company MN now owns 12,378,331 shares of the medical technology company’s stock valued at $962,664,000 after acquiring an additional 165,149 shares in the last quarter. Hedge funds and other institutional investors own 81.72% of the company’s stock.
MDT has been the subject of several recent analyst reports. Bank of America raised shares of Medtronic from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Royal Bank of Canada cut their price objective on shares of Medtronic from $90.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, October 9th. SunTrust Banks set a $92.00 price objective on shares of Medtronic and gave the stock a “buy” rating in a research report on Sunday, November 19th. Jefferies Group reaffirmed a “buy” rating and set a $99.00 price objective on shares of Medtronic in a research report on Thursday, November 23rd. Finally, Northland Securities reaffirmed a “hold” rating and set a $80.00 price objective on shares of Medtronic in a research report on Wednesday, November 22nd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and fifteen have given a buy rating to the company’s stock. Medtronic presently has a consensus rating of “Buy” and an average price target of $89.65.
In related news, EVP Bryan C. Hanson sold 16,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $82.82, for a total value of $1,325,120.00. Following the completion of the transaction, the executive vice president now owns 88,818 shares in the company, valued at approximately $7,355,906.76. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Richard Kuntz sold 78,526 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $86.21, for a total transaction of $6,769,726.46. Following the completion of the transaction, the vice president now owns 149,761 shares of the company’s stock, valued at approximately $12,910,895.81. The disclosure for this sale can be found here. In the last quarter, insiders sold 136,684 shares of company stock valued at $11,582,596. 0.31% of the stock is owned by company insiders.
Medtronic plc. (NYSE:MDT) opened at $85.45 on Monday. The stock has a market cap of $115,660.00, a P/E ratio of 23.48, a P/E/G ratio of 2.35 and a beta of 0.99. Medtronic plc. has a fifty-two week low of $73.59 and a fifty-two week high of $89.72. The company has a quick ratio of 2.05, a current ratio of 2.40 and a debt-to-equity ratio of 0.50.
Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.08. The business had revenue of $7.05 billion during the quarter, compared to analyst estimates of $7.05 billion. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The firm’s quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter last year, the business earned $1.12 EPS. equities analysts expect that Medtronic plc. will post 4.77 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 19th. Investors of record on Friday, December 29th will be issued a $0.46 dividend. The ex-dividend date is Thursday, December 28th. This represents a $1.84 dividend on an annualized basis and a yield of 2.15%. Medtronic’s dividend payout ratio (DPR) is presently 50.55%.
TRADEMARK VIOLATION WARNING: “F&V Capital Management LLC Decreases Holdings in Medtronic plc. (MDT)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/15/fv-capital-management-llc-decreases-holdings-in-medtronic-plc-mdt.html.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.